Amgen strives to continuously align its responsibility programs with the expectations of internal and external stakeholders. In particular, we focus on those issues that are considered to be important priorities for stakeholders and that align with Amgen’s mission, values and strategy.
In 2017, Amgen conducted a stakeholder assessment to update and enhance our understanding of the responsibility issues of greatest importance to internal and external stakeholders. We gathered information from stakeholders using direct interviews, online surveys, group discussions and review of relevant published material. We surveyed internal stakeholders to understand their perspectives on issues that impact Amgen’s business. External stakeholders surveyed included patient advocacy organizations, corporate social responsibility-focused non-government organizations, investors and organizations devoted to promoting access to medicine. We are using the information we gained to help shape our approach to programs and reporting as we move forward.
Stakeholder Assessment Results
While all issues included in this assessment are important, this graph shows that, in the view of a variety of stakeholders, enhancing access to medicine, making safe and effective medicines and conducting business in an ethical manner are currently the highest priority issues.